NeuroSense Phase 2b ALS Trial Achieves Primary Safety/Tolerability & Secondary Clinical Efficacy Endpoints

 

• Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include:
  • PrimeC achieved primary safety and tolerability endpoints with a safety and tolerability profile comparable to placebo
  • Meaningful slowing of disease progression: 29% difference (P=0.12) in favor of ALSFRS-R outcome for patients treated with PrimeC vs placebo
  • Slow Vital Capacity: observed a positive trend in favor of patients treated with PrimeC compared to placebo
• Neurofilament biomarker results from Biogen collaboration expected in January 2024
• Primary biomarker endpoints and exploratory biomarkers from this trial, expected in H1 2024
• Company to host webcast conference call to present data today at 8:30 AM EST

https://www.prnewswire.com/news-releases/neurosenses-phase-2b-als-trial-achieves-primary-safety-and-tolerability--secondary-clinical-efficacy-endpoints-302005837.html